LINK TO ONE OF OUR 57 MEMBER ASSOCIATIONS FOR LOCAL SUPPORT, ADVICE AND NEWS

view map
close
  • Finland
  • Norway
  • Sweden
  • Estonia
  • Russian Federation
  • Latvia
  • Denmark
  • Lithuania
  • United Kingdom
  • Netherlands
  • Ireland
  • Poland
  • Germany
  • Belgium
  • Czech Republic
  • Ukraine
  • Slovakia
  • Luxembourg
  • Moldova, Republic of
  • Austria
  • France
  • Switzerland
  • Romania
  • Slovenia
  • Croatia
  • Serbia
  • Bosnia & Herzegovina
  • Bulgaria
  • Italy
  • Macedonia, the Former Yugoslav Republic of
  • Spain
  • Greece
  • Israel

AVROBIO Announces New Patients Dosed In Gaucher Disease and Cystinosis Clinical Trials

6 July 2020

AVROBIO has announced that the first patient has been dosed in their Phase 1/2 GuardOne trial of AVR-RD-02, AVROBIO’s investigational gene therapy for Gaucher disease type 1.

Our CEO Tanya Collin-Histed says "This is exciting news for the Gaucher community as Gene Therapy is finally being investigated to evaluate the safety and efficacy in a clinical trial."

The study is actively recruiting in Australia and Canada and plans to open additional clinical sites in the U.S. and Israel by the end of 2020.

For the full press release, visit here